An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease
Yanchun Peng,Suet Ling Felce,Danning Dong,Frank Penkava,Alexander J. Mentzer,Xuan Yao,Guihai Liu,Zixi Yin,Ji-Li Chen,Yongxu Lu,Dannielle Wellington,Peter A. C. Wing,Delaney C. C. Dominey-Foy,Chen Jin,Wenbo Wang,Megat Abd Hamid,Ricardo A. Fernandes,Beibei Wang,Anastasia Fries,Xiaodong Zhuang,Neil Ashley,Timothy Rostron,Craig Waugh,Paul Sopp,Philip Hublitz,Ryan Beveridge,Tiong Kit Tan,Christina Dold,Andrew J. Kwok,Charlotte Rich-Griffin,Wanwisa Dejnirattisa,Chang Liu,Prathiba Kurupati,Isar Nassiri,Robert A. Watson,Orion Tong,Chelsea A. Taylor,Piyush Kumar Sharma,Bo Sun,Fabiola Curion,Santiago Revale,Lucy C. Garner,Kathrin Jansen,Ricardo C. Ferreira,Moustafa Attar,Jeremy W. Fry,Rebecca A. Russell,Hans J. Stauss,William James,Alain Townsend,Ling-Pei Ho,Paul Klenerman,Juthathip Mongkolsapaya,Gavin R. Screaton,Calliope Dendrou,Stephen N. Sansom,Rachael Bashford-Rogers,Benny Chain,Geoffrey L. Smith,Jane A. McKeating,Benjamin P. Fairfax,Paul Bowness,Andrew J. McMichael,Graham Ogg,Julian C. Knight,Tao Dong,
DOI: https://doi.org/10.1038/s41590-021-01084-z
IF: 30.5
2021-12-01
Nature Immunology
Abstract:Abstract NP 105–113 -B*07:02-specific CD8 + T cell responses are considered among the most dominant in SARS-CoV-2-infected individuals. We found strong association of this response with mild disease. Analysis of NP 105–113 -B*07:02-specific T cell clones and single-cell sequencing were performed concurrently, with functional avidity and antiviral efficacy assessed using an in vitro SARS-CoV-2 infection system, and were correlated with T cell receptor usage, transcriptome signature and disease severity (acute n = 77, convalescent n = 52). We demonstrated a beneficial association of NP 105–113 -B*07:02-specific T cells in COVID-19 disease progression, linked with expansion of T cell precursors, high functional avidity and antiviral effector function. Broad immune memory pools were narrowed postinfection but NP 105–113 -B*07:02-specific T cells were maintained 6 months after infection with preserved antiviral efficacy to the SARS-CoV-2 Victoria strain, as well as Alpha, Beta, Gamma and Delta variants. Our data show that NP 105–113 -B*07:02-specific T cell responses associate with mild disease and high antiviral efficacy, pointing to inclusion for future vaccine design.
immunology